Completed PHASE2 INTERVENTIONAL 2-arm NCT01157065

Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration (RACE)

Controlled, Double-Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD

Sponsor: Alcon Research

Conditions Exudative Age-Related Macular Degeneration

Updated 6 times since 2017 Last updated: Apr 19, 2013 Started: Jun 30, 2011 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Exudative Age-Related Macular Degeneration, this trial is completed. The trial is conducted by Alcon Research and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alcon Research

Data source: Alcon Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fort Worth, United States